Lecanemab
In News The drug, lecanemab, jointly developed by pharma companies Biogen and Eisai, was tested on patients with early Alzheimer’s. About Lecanemab Lecanemab belongs to a class of drugs called monoclonal antibodies. These antibody-mediated drugs target beta-amyloid, the protein deposition that is seen in patients with Alzheimer’s disease, and disrupts cell function. Lecanemab appears to […]